To sum up, GH001 has shown us pretty robust efficacy, a strong safety profile, and durable antidepressant effects. Going into ...
Biohaven didn't receive the clinical readout it was hoping for over the festive period. | As the biopharma wound down for the ...
Biohaven's Phase 2 study with BHV-7000 in MDD did not meet its primary endpoint of reducing depressive symptoms in comparison ...
GH Research ( ($GHRS) ) just unveiled an update. On January 5, 2026, GH Research announced that the U.S. Food and Drug Administration lifted the ...
Vegans and vegetarian diets might seem like the healthy choice, but scientists now say that avoiding meat could scupper your ...
As of Monday, January 05, NRx Pharmaceuticals, Inc.’s NRXP share price has dipped by 9.16%, which has investors questioning ...
Baystreet.ca News Commentary – Pharmaceutical markets are witnessing drug delivery devices surge toward $862.16 billion by ...
There are plenty of things we could dwell on as standout themes for the year gone by, but the one that looms largest in our ...
Stocktwits on MSN
Biohaven’s phase II depression trial falls short, but analysts downplay impact – Wall Street looks ahead to epilepsy data
Analyst Myles Minter noted that the company’s pivotal Phase III study of BHV-7000 in focal-onset epilepsy in the first half ...
New Jersey is poised to become one of the first states on the East Coast to establish a regulated framework for psilocybin-assisted therapy. On Nov. 24, the Assembly Health Committee approved Assembly ...
BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% ...
ADHD medications work like sleep, not attention boosters, massive brain study reveals. For some kids, focus problems may be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback